About InVivoSIM anti-human integrin α4β1 (VLA-4) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Natalizumab making it ideal for research use. This Natalizumab biosimilar reacts with human VLA-4 α chain also known as CD49d and integrin alpha 4. VLA-4 is a 150 kDa glycoprotein belonging to the integrin family that is expressed by many cell types including T and B lymphocytes, monocytes, eosinophils, basophils, mast cells, thymocytes, NK cells, and dendritic cells. Integrin α4 associates with integrin β7 to form integrin α4β7 also known as LPAM-1 as well as integrin β1 (CD29) to form integrin α4β1 also known as VLA-4. Integrin α4 plays roles in adhesion and T cell co-stimulation. Integrin α4 ligands include VCAM-1, MAdCAM-1, and fibronectin. InVivoSIM anti-human integrin α4β1 (VLA-4) Specifications IsotypeHuman IgG4, κ Recommended Isotype Control(s)InVivoMAb polyclonal human IgG Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman integrin α4β7 Reported ApplicationsFunctional assaysFlow cytometry FormulationPBS, pH 7.0Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95%Determined by SDS-PAGE Sterility0.2 μm filtered PurificationProtein G RRIDAB_2927534 Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
